NCT03634514Unknown4 期
National, Monocentric, Randomized, Double-blind, Controlled, Crossover Clinical Trial, to Evaluate the Non-inferiority of Pain Intensity After the Application of Recombinant Human Somatropin - Biomatrop (Biosintética Farmacêutica) in Relation to Recombinant Human Somatotropin - Hormotrop (Bergamo), Single Dose, in Healthy Subjects of Both Genders
Ache Laboratorios Farmaceuticos S.A.1 个研究点 分布在 1 个国家目标入组 68 人开始时间: 2018年8月27日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 68
- 试验地点
- 1
- 主要终点
- Pain Intensity
研究概览
简要总结
Randomized, Double-blind, Controlled, Crossover, in which 68 subjects (34 males and 34 females) will receive, in each stage, an application of 4 UI, subcutaneous, single dose, of the investigational drug (Recombinant Human Somatropin - Biomatrop) and the comparator (Recombinant Human Somatropin - Hormotrop) according to randomization to evaluate the Non-inferiority of Pain Intensity After the Application of Hormotrop, using Visual Analogue Scale (0-10cm) and record the incidence of adverse events.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Supportive Care
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Skin phototype from 2 to 4, according to Fitspatrick classification: http://www.sbd.org.br/dermatologia/pele/cuidados/classifica cao-dos-fototipos-de-pele/ ;
- •Subjects with normal laboratory, type 1 urine exam, vital signs and ECG results;
- •Weight ≥ 50kg and Body Mass Index ≤ 30 ;
- •Healthy subject according with clinical history
- •Ability to understand and consent their participation in this clinical study, expressed by signing the Informed Consent Form (ICF);
- •Subject who have negative results for stool protoparasitological examination accomplished in clinical study. Subjects with positive results for Endolimax nana, Entamoeba hartmanni, Entamoeba coli, Iodamoeva btshlii, Chilomastix mesili, Trichomonas hominis, Retortamonas intestinalis e Enteromonas hominis will be able to be included in the study. At the end of the study those subjects will be guided to treatment according to clinic investigator criteria.
排除标准
- •Laboratory and clinical exam results out of normal range values, unless considered by physician clinically irrelevant;
- •Positive sorology for HIV;
- •Positive sorology for Hepatitis B;
- •Positive sorology for Hepatitis C;
- •Known hypersensitivity to the components of the medicines used during the study or related chemical compounds;
- •Subjects that has participated in clinical trial protocols in the last twelve (12) months (National Board of Health- Resolution 251 of 07 August 1997, Part III, sub-item J), unless the investigator considers that there may be a direct benefit to it;
- •Use of any type of regular medication within two (2) weeks or five (5) half-lives (whichever lasts longer) before administration of the first dose of the investigational product (IP). The eventual use of medication, which in the opinion of the Principal Investigator or physician does not interfere with the pharmacokinetics of IP in study will not be considered as exclusion criteria;
- •History of alcohol abuse or having ingested alcoholic drink 24 hours prior to IP administration;
- •History of psychotropic drug use and / or positive outcome for any of the components of the drug abuse test for amphetamine, benzoylecgonine (cocaine), benzodiazepines, methamphetamine, opiates, morphine, etrahydrocannabinol-THC (Marijuana / Marijuana). Subjects who used marijuana and hashish in less than three months before the consultation will be excluded. For drugs like cocaine, crack and heroin will be excluded subjects who present any use history;
- •Any finding of clinical observation, laboratory abnormality or therapy which, in the opinion of the investigator, may put the subject at risk or interfere with the purpose of the study;
- •The subject have any condition that in investigator's opinion prevents him/her from participating in the study;
- •History of food allergy or hyperactivity to medications or food;
- •Regular smokers or ex-smokers who have stopped for less than 6 months;
- •Subjects who have a relationship of kinship to second degree or any bond with the sponsor or research center employees;
- •Subjects with the following ECG changes: sinus tachycardia with heart rate ˃ 120 bpm; bradycardia sinus heart rate <50 bpm; atrial tachycardia, ventricular or junctional; ectopic atrial rhythm; atrial fibrillation; atrial flutter; accelerated idioventricular rhythm; locking atrium ventricular (BAV) of 1º, 2º and 3º degrees; ventricular pre-excitation; complete blockage of right or left branch; rhythm of pacemaker; supraventricular tachycardia (nodal tachycardia, ventricular atrial tachycardia) or any other clinically significant;
- •Male subjects who do not agree to use acceptable contraceptive methods: (a) contraceptive methods for the participant: barrier preservative, except for (vasectomy) or for participants who declare that they do not engage in sexual practices or exercise them non-reprodutively; (b) contraceptive methods for the partner: oral contraceptive, intravenous contraceptive, intrauterine device (IUD), hormonal implant, hormonal transdermal patch, tubal ligation, and barrier methods except for female partners that are surgically sterile (bilateral oophorectomy or hysterectomy), or menopause for at least 01 (one) year;
- •Women who do not agree to use acceptable contraceptive methods (oral contraceptive, intravenous contraceptive, intrauterine device (IUD), hormonal implant, barrier methods, hormonal transdermal patch and tubal ligation); except for those surgically sterile (bilateral oophorectomy or hysterectomy), menopause for at least one year, and participants who report not engaging in sexual practices or non-reproductive practices;
- •Women in pregnancy or nursing period.
研究组 & 干预措施
Application of Biomatrop
Experimental
A single dose of Recombinant Human Somatropin - Biomatrop is administered. The pain intensity is evaluated using visual analogue scale (0-10cm) and record the incidence of adverse events.
干预措施: Recombinant human growth hormone - Biomatrop (Drug)
Application of Biomatrop
Experimental
A single dose of Recombinant Human Somatropin - Biomatrop is administered. The pain intensity is evaluated using visual analogue scale (0-10cm) and record the incidence of adverse events.
干预措施: Recombinant human growth hormone - Hormotrop (Drug)
Application of Hormotrop
Active Comparator
A single dose of Recombinant Human Somatropin - Hormotrop is administered. The pain intensity is evaluated using visual analogue scale (0-10cm) and record the incidence of adverse events.
干预措施: Recombinant human growth hormone - Biomatrop (Drug)
Application of Hormotrop
Active Comparator
A single dose of Recombinant Human Somatropin - Hormotrop is administered. The pain intensity is evaluated using visual analogue scale (0-10cm) and record the incidence of adverse events.
干预措施: Recombinant human growth hormone - Hormotrop (Drug)
结局指标
主要结局
Pain Intensity
时间窗: 1 hour
Report the Pain Intensity using Visual Analogue Scale (0-10cm)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Study on Foster Efficacy Maintenance and Reliever vs Foster Maintenance + Salbutamol Reliever in Asthmatics (MART2)AsthmaNCT00861926Chiesi Farmaceutici S.p.A.1,714
Unknown
不适用
The Effect of a New Infant Formula on Growth and Cognition in Healthy Term InfantsChild DevelopmentNCT04508257Heilongjiang Feihe Dairy Co. Ltd.450
Unknown
不适用
Safety and Nutritional Adequacy of a New Infant Formula in Healthy Term InfantsChild DevelopmentNCT04013087Heilongjiang Feihe Dairy Co. Ltd.450
已完成
不适用
A Randomized, Sham-controlled Study of gammaCore ® (nVNS) for Prevention of Episodic MigraineMigraineNCT02378844ElectroCore INC477
Unknown
3 期
Evaluate the Efficacy and Safety of Short-term Administration of SIMDAXAcute Decompensated Heart FailureNCT03555123Yooyoung Pharmaceutical Co., Ltd.112